James Lanthier's guest appearances

James Lanthier

Psychedelics Today

The Entheogenic Evolution

The Resilient Advisor

Psychedelic Insiders

Psychedelic Spotlight Podcast

Grizzle Pod: Thematic Growth Investing

This One Time On Psychedelics

Payton Nyquvest

Daniel Carcillo

Doug Drysdale

Timothy Ko

Michelle Janikian

Pierre Bouchard

Patrick Moher

Ed Prideaux

Matthew Johnson

Paul Austin

Mike Crowley

Josh Bartch

Brett Greene

Rick Doblin

Rebecca Martinez

OwlTail

I imagine for all of us that have been curious &amp; interested in the realm of psychedelic medicines for some time now, it is easy to see that the landscape surrounding the industry of these medicines is developing &amp; shifting rapidly. While many people are focused on wanting things to stay the same way they were, others of us recognize that with anything in life, change is the only status quo &amp; as such, it leaves us with questions such as where the industry be going, what new exciting opportunities are opening up &amp; what we can expect to see moving forward. Todays guest on the show is a gentleman who is at the forefront of this revolution &amp; someone I am extremely interested in conversing with to get his thoughts on these questions &amp; more. He is a seasoned technology executive equipped with strong expertise in realms such as corporate finance, public markets &amp; M&amp;A. Most recently, he was the co-founder &amp; CEO of Future Fertility, which was focused on AI applications for human infertility before moving into his newest project as CEO of Mindset Pharma. Mindset Pharma is a company who’s mission it is to be on the cutting edge of developing next generation psychedelic medicines to treat neurological &amp; psychiatric disorders &amp; in this episode, we will be expanding upon his mission within this company, how he first became interested in the business of psychedelic medicines to help the world at large heal &amp; much, much more.Show Notes:(1:15) Jame’s Bio.(2:37) How did James get into the business of psychedelics?(8:42) What are the challenges regarding psychedelic usage?(12:36) What kind of new psychedelics is James creating?(22:04) The most interesting part of James’ work.(33:38) The future of psychedelics.(41:27) What has been the most fulfilling part of James’ life/business?   (46:47) Where you can reach James!(47:41) One final question…About James LanthierJames Lanthier, CEO of Mindset Pharma is a seasoned technology executive with strong expertise in corporate finance, public markets and M&amp;A. Most recently, Mr. Lanthier was a co-founder and CEO of Future Fertility, an innovative early stage developer of AI applications for human infertility. As a C-Suite executive, Mr. Lanthier has assisted in the growth and successful exit of numerous technology-enabled businesses through the public markets, including Mood Media, the world’s largest in-store media provider, and Fun Technologies, a pioneer in online casual games.Connect with Jameshttps://twitter.com/MindsetPharma https://twitter.com/JamesLanthier https://www.linkedin.com/company/mindset-pharma-inc/ https://www.linkedin.com/in/james-lanthier-243b9791/ Check us out at Highlyoptimzed.meThank you to Freedom Builderz for Making this Podcast Possible!Building online platforms for visionaries &amp; influencers.https://www.freedombuilderz.com/ This episode was produced by Mazel Tov Media in Quincy, Massachusetts.https://www.highlyoptimized.me

I imagine for all of us that have been curious &amp; interested in the realm of psychedelic medicines for some time now, it is easy to see that the landscape surrounding the industry of these medicines is developing &amp; shifting rapidly. While many people are focused on wanting things to stay the same way they were, others of us recognize that with anything in life, change is the only status quo &amp; as such, it leaves us with questions such as where the industry be going, what new exciting opportunities are opening up &amp; what we can expect to see moving forward. Todays guest on the show is a gentleman who is at the forefront of this revolution &amp; someone I am extremely interested in conversing with to get his thoughts on these questions &amp; more. He is a seasoned technology executive equipped with strong expertise in realms such as corporate finance, public markets &amp; M&amp;A. Most recently, he was the co-founder &amp; CEO of Future Fertility, which was focused on AI applications for human infertility before moving into his newest project as CEO of Mindset Pharma. Mindset Pharma is a company who’s mission it is to be on the cutting edge of developing next generation psychedelic medicines to treat neurological &amp; psychiatric disorders &amp; in this episode, we will be expanding upon his mission within this company, how he first became interested in the business of psychedelic medicines to help the world at large heal &amp; much, much more. Show Notes:(1:15) Jame’s Bio.(2:37) How did James get into the business of psychedelics?(8:42) What are the challenges regarding psychedelic usage?(12:36) What kind of new psychedelics is James creating?(22:04) The most interesting part of James’ work.(33:38) The future of psychedelics.(41:27) What has been the most fulfilling part of James’ life/business?   (46:47) Where you can reach James!(47:41) One final question… About James LanthierJames Lanthier, CEO of Mindset Pharma is a seasoned technology executive with strong expertise in corporate finance, public markets and M&amp;A. Most recently, Mr. Lanthier was a co-founder and CEO of Future Fertility, an innovative early stage developer of AI applications for human infertility. As a C-Suite executive, Mr. Lanthier has assisted in the growth and successful exit of numerous technology-enabled businesses through the public markets, including Mood Media, the world’s largest in-store media provider, and Fun Technologies, a pioneer in online casual games.Connect with James<a href="https://twitter.com/MindsetPharma" rel="nofollow" target="_blank">https://twitter.com/MindsetPharma</a><a href="https://twitter.com/JamesLanthier" rel="nofollow" target="_blank"> </a><a href="https://twitter.com/JamesLanthier" rel="nofollow" target="_blank">https://twitter.com/JamesLanthier</a><a href="https://www.linkedin.com/company/mindset-pharma-inc/" rel="nofollow" target="_blank"> </a><a href="https://www.linkedin.com/company/mindset-pharma-inc/" rel="nofollow" target="_blank">https://www.linkedin.com/company/mindset-pharma-inc/</a><a href="https://www.linkedin.com/in/james-lanthier-243b9791/" rel="nofollow" target="_blank"> </a><a href="https://www.linkedin.com/in/james-lanthier-243b9791/" rel="nofollow" target="_blank">https://www.linkedin.com/in/james-lanthier-243b9791/</a> Check us out at <a href="https://www.highlyoptimized.me/" rel="nofollow" target="_blank">Highlyoptimzed.me</a>Thank you to Freedom Builderz for Making this Podcast Possible!Building online platforms for visionaries &amp; influencers.<a href="https://www.freedombuilderz.com/" rel="nofollow" target="_blank">https://www.freedombuilderz.com/</a> This episode was produced by Mazel Tov Media in Quincy, Massachusetts.<a href="https://www.highlyoptimized.me/" rel="nofollow" target="_blank">https://www.highlyoptimized.me</a>

Episode 108: The Future Of Psychedelic Healthcare (feat. James Lanthier)

In our second episode of the Management 1x1 Series we are thrilled to have James Lanthier, CEO of Mindset Pharma join us. Mindset is one of the world's leading companies in the field of psychedelic medicines to treat neurological and psychiatric disorders. James brings a wealth of insight to the pod and breaks down the big picture of the true disruption happening in the psychedelics industry - enjoy the interview. Segments: 0:40 What's the opportunity set and how disruptive are psychedelics? 4:58 Where are we in terms of cultural and medical acceptance of psychedelics? 9:26 Mindset Pharma's science driven focus in the sector 13:42 Understanding the process of enhancing 1st generation psychedelic drugs. 18:45 Mindset's partnership with big pharma - Otsuka Pharmaceuticals, understanding the validation and importance for the industry. 23:40 The asset light nature of the business model. 25:13 The outlook for the psychedelics industry and what separates winners from losers?

In our second episode of the Management 1x1 Series we are thrilled to have James Lanthier, CEO of Mindset Pharma join us. Mindset is one of the world's leading companies in the field of psychedelic medicines to treat neurological and psychiatric disorders. James brings a wealth of insight to the pod and breaks down the big picture of the true disruption happening in the psychedelics industry - enjoy the interview. Segments: 0:40 What's the opportunity set and how disruptive are psychedelics? 4:58 Where are we in terms of cultural and medical acceptance of psychedelics? 9:26 Mindset Pharma's science driven focus in the sector 13:42 Understanding the process of enhancing 1st generation psychedelic drugs. 18:45 Mindset's partnership with big pharma - Otsuka Pharmaceuticals, understanding the validation and importance for the industry. 23:40 The asset light nature of the business model. 25:13 The outlook for the psychedelics industry and what separates winners from losers?

Management 1x1 Series: James Lanthier, CEO of Mindset Pharma - The Future of Psychedelics

My guest this week is James Lanthier, CEO of Mindset Pharma of Toronto, Canada, a company that is seeking to develop novel psychedelic analogues to existing psychedelics such as psilocybin, DMT, and 5-MeO-DMT for more targeted delivery, efficacy, and therapeutic potential for use in the developing psychedelic healthcare field. You can find them online at www.mindsetpharma.com 

My guest this week is James Lanthier, CEO of Mindset Pharma of Toronto, Canada, a company that is seeking to develop novel psychedelic analogues to existing psychedelics such as psilocybin, DMT, and 5-MeO-DMT for more targeted delivery, efficacy, and therapeutic potential for use in the developing psychedelic healthcare field. You can find them online at <a href="http://www.mindsetpharma.com" rel="nofollow" target="_blank">www.mindsetpharma.com</a>

Episode 195: Mindset Pharma with James Lanthier

In this episode of the podcast, Joe interviews James Lanthier, the CEO of Mindset Pharma; a biotechnology company discovering and developing new (and hopefully safer, more predictable, and more palatable) psychedelic compounds. www.psychedelicstoday.com

In this episode of the podcast, Joe interviews James Lanthier, the CEO of Mindset Pharma; a biotechnology company discovering and developing new (and hopefully safer, more predictable, and more palatable) psychedelic compounds. <a href="http://www.psychedelicstoday.com" rel="nofollow" target="_blank">www.psychedelicstoday.com</a>

PT332 – James Lanthier – Patentability, Capitalism, and The Next Generation of Psychedelics

Mindset Pharma is a biotechnology company developing medications and synthesis processes for the medical psychedelic market. On this episode of The Investment Spotlight Show, Jay Coulter and Chris Versace interview Mindset CEO James Lanthier. $MSET Follow Resilient Advisor™ On Social: -- Twitter: https://twitter.com/sjaycoulter -- Facebook: https://www.facebook.com/resilientadvisor -- LinkedIn: https://www.linkedin.com/in/sjaycoulter -- Instagram: https://www.instagram.com/sjaycoulter Learn more about Resilient Advisor™: https://www.resilientadvisor.com © Resilient Advisor. All Rights Reserved

Mindset Pharma is a biotechnology company developing medications and synthesis processes for the medical psychedelic market. On this episode of The Investment Spotlight Show, Jay Coulter and Chris Versace interview Mindset CEO James Lanthier. $MSET Follow Resilient Advisor™ On Social: -- Twitter: <a href="https://twitter.com/sjaycoulter" rel="nofollow" target="_blank">https://twitter.com/sjaycoulter</a> -- Facebook: <a href="https://www.facebook.com/resilientadvisor" rel="nofollow" target="_blank">https://www.facebook.com/resilientadvisor</a> -- LinkedIn: <a href="https://www.linkedin.com/in/sjaycoulter" rel="nofollow" target="_blank">https://www.linkedin.com/in/sjaycoulter</a> -- Instagram: <a href="https://www.instagram.com/sjaycoulter" rel="nofollow" target="_blank">https://www.instagram.com/sjaycoulter</a> Learn more about Resilient Advisor™: <a href="https://www.resilientadvisor.com" rel="nofollow" target="_blank">https://www.resilientadvisor.com</a> © Resilient Advisor. All Rights Reserved

Ep205 Investment Spotlight: Mindset Pharma with James Lanthier

In this episode of the Psychedelic Spotlight podcast we chat with James Lanthier, CEO of Mindset Pharma, a Toronto based drug discovery company focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC Markets under the symbol $MSSTF.In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.*To learn more about Mindset Pharma, visit their website: MindsetPharma.com*Subscribe to our newsletter to get the latest industry news: PsychedelicSpotlight.com

In this episode of the Psychedelic Spotlight podcast we chat with James Lanthier, CEO of Mindset Pharma, a Toronto based drug discovery company focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC Markets under the symbol $MSSTF.In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.*To learn more about Mindset Pharma, visit their website: <a href="https://www.mindsetpharma.com" rel="nofollow" target="_blank">MindsetPharma.com</a>*Subscribe to our newsletter to get the latest industry news: <a href="https://psychedelicspotlight.com/" rel="nofollow" target="_blank">PsychedelicSpotlight.com</a>

James Lanthier, CEO, Mindset Pharma

Episode 5 - June 10th 2020James Lanthier - CEO at Mindset PharmaPresented by Paul AustinMindset PharmaMindset is a psychedelic-based biopharmaceutical company that is focused on creating and developing a proprietary library of novel and patentable psychedelic therapeutics for the treatment of neurological and psychiatric disorders. James Lanthier is a seasoned technology executive with strong expertise in business building and corporate finance. Most recently, Mr. Lanthier co-founded Future Fertility, the leading developer of Artificial Intelligence applications for human infertility. Previously, was a founder and COO of Mood Media Corporation, which he grew along with the founding team to be the world's largest in-store media provider, serving over 300,000 retail and hospitality locations around the globe.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company. 

Episode 5 - June 10th 2020<ul><li>James Lanthier - CEO at <a href="https://www.mindsetpharma.com/" rel="noopener noreferrer nofollow" target="_blank">Mindset Pharma</a></li><li>Presented by <a href="https://thethirdwave.co/" rel="noopener noreferrer nofollow" target="_blank">Paul Austin</a></li></ul>Mindset PharmaMindset is a psychedelic-based biopharmaceutical company that is focused on creating and developing a proprietary library of novel and patentable psychedelic therapeutics for the treatment of neurological and psychiatric disorders. James Lanthier is a seasoned technology executive with strong expertise in business building and corporate finance. Most recently, Mr. Lanthier co-founded Future Fertility, the leading developer of Artificial Intelligence applications for human infertility. Previously, was a founder and COO of Mood Media Corporation, which he grew along with the founding team to be the world's largest in-store media provider, serving over 300,000 retail and hospitality locations around the globe.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.